You are viewing a preview of...

Modulating a Hypothalamic Switch to Treat Obesity

The administration of a dual PTP1B and TCPTP inhibitor to the brain or systemically can promote weight loss

Background

The rising prevalence of obesity and associated medical issues is an ongoing challenge.

Technology Overview

A hypothalamic protein tyrosine phosphatase (PTP) ‘switch’, regulated by glucocorticoids (GC), modulates insulin sensitivity and weight loss. CNS-targeted blocking of TCPTP (via GC-receptor antagonism) reset in diet-induced obesity (DIO) re-sensitizes arcuate nucleus (ARC) neurons to insulin, increases energy expenditure and white adipose tissue (WAT) browning leading to weight loss. Combined with targeting PTP1B to re-sensitize ARC neurons to leptin, this represses feeding and leads to synergistic and sustained weight loss and improved glucose metabolism. Alternatively, the administration of a dual PTP1B and TCPTP inhibitor to the brain or systemically, can promote weight loss and improve glucose homeostasis in DIO.

, .

Targets have been

Log in or create a free account to continue reading